

Pharmacy and Therapeutics Committee Virtual Meeting

May 19, 2021

12:00pm - 5:00pm

Zoom Meeting Registration: https://ahcccs.zoom.us/webinar/register/WN_AvFfok-xRwmpKIFRNlyPbw

Time	Topic
12:00 PM	<p>Welcome and Introductions: Suzi Berman, RPh, AHCCCS Pharmacy Director</p> <ul style="list-style-type: none"> ● January 26, 2021 - P&T Minutes Review and Vote ● All submitted written testimony will be posted on the AHCCCS website under Pharmacy/Pharmacy & Therapeutics Committee ● The HIV agenda item from the last meeting will be incorporated into the full review of HIV medications to be presented at the October meeting.
12:15 PM	<p>Conflict of Interest Training: AHCCCS Office of Administrative Legal Services – Susan Russo</p>
1:00 PM	<p>Supplemental Rebate Class Reviews: Clinical reviews by Hind Douiki, PharmD, Magellan</p> <ol style="list-style-type: none"> 1. Analgesics – Narcotics Long-Acting Agents <ol style="list-style-type: none"> a. Public Testimony: None 2. Antibiotics, Inhaled <ol style="list-style-type: none"> a. Public Testimony: None 3. Anticoagulants <ol style="list-style-type: none"> a. Public Testimony: None 4. Antimigraine Agents - Other <ol style="list-style-type: none"> a. Public Testimony: None 5. Antipsychotic – Oral Atypicals 2nd Generation <ol style="list-style-type: none"> a. Public Testimony: None 6. Antipsychotics – Atypical Long-Acting Injectables <ol style="list-style-type: none"> a. Public Testimony: None 7. COPD Agents <ol style="list-style-type: none"> a. Public Testimony: None 8. Cytokine and CAM Antagonists <ol style="list-style-type: none"> a. Public Testimony: None 9. Epinephrine, Self-Injected <ol style="list-style-type: none"> a. Public Testimony: None

	<p>10. Glucagon Agents a. Public Testimony: None</p> <p>11. Glucocorticoids – Inhaled a. Public Testimony: None</p> <p>12. Growth Hormone a. Public Testimony: None</p> <p>13. Hepatitis C Agents – Other a. Public Testimony: None</p> <p>14. Hepatitis C DAA Agents a. Public Testimony: None</p> <p>15. Hypoglycemics, Incretin Mimetics/Enhancers a. Public Testimony: None</p> <p>16. Hypoglycemics – Insulin and Related Agents a. Public Testimony: None</p> <p>17. Opioid Dependence Agents a. Public Testimony: Oral i. Megan Aronson ii. Steven Locnikar, DO</p> <p>18. Pancreatic Enzymes a. Public Testimony: None</p> <p>19. Progestational Agents a. Public Testimony: None</p> <p>20. Stimulants and Related Agents a. Public Testimony: None</p> <p>21. Skin Substitutes a. Public Testimony i. Katie Artz, MD ii. Bashar Majeed, MD</p>
--	--

<p>2:30 PM</p>	<p>New Drug Reviews: Hind Douiki, PharmD, Magellan</p> <table border="0"> <thead> <tr> <th data-bbox="324 1732 487 1764"><u>Brand Name</u></th> <th data-bbox="657 1732 852 1764"><u>Generic Name</u></th> </tr> </thead> <tbody> <tr> <td data-bbox="324 1774 487 1806">1. Bronchitol</td> <td data-bbox="657 1774 852 1806">Mannitol</td> </tr> <tr> <td data-bbox="324 1816 487 1848">2. Cabenuva</td> <td data-bbox="657 1816 852 1848">Cabotegravir/Rilpivirine</td> </tr> <tr> <td data-bbox="324 1858 487 1890">3. Gemtesa</td> <td data-bbox="657 1858 852 1890">Vibegron</td> </tr> <tr> <td data-bbox="324 1900 487 1932">4. Lupkynis</td> <td data-bbox="657 1900 852 1932">Voclosporin</td> </tr> <tr> <td data-bbox="324 1942 487 1974">5. Ponvory</td> <td data-bbox="657 1942 852 1974">Ponesimod</td> </tr> </tbody> </table>	<u>Brand Name</u>	<u>Generic Name</u>	1. Bronchitol	Mannitol	2. Cabenuva	Cabotegravir/Rilpivirine	3. Gemtesa	Vibegron	4. Lupkynis	Voclosporin	5. Ponvory	Ponesimod
<u>Brand Name</u>	<u>Generic Name</u>												
1. Bronchitol	Mannitol												
2. Cabenuva	Cabotegravir/Rilpivirine												
3. Gemtesa	Vibegron												
4. Lupkynis	Voclosporin												
5. Ponvory	Ponesimod												

	6. Verquvo 7. Vocabria	Vericiguat Cabotegravir
3:00 PM	Break & Executive Session: Chris Andrews, PharmD, Magellan	
4:30 PM	Public Therapeutic Class Votes: Hind Douiki, PharmD, Magellan	
5:00 PM	Meeting Adjournment Future Meeting Dates: October 18, 2021 January 19, 2022	